Journal
PHARMACOGENOMICS
Volume 9, Issue 10, Pages 1521-1530Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/14622416.9.10.1521
Keywords
audiometric; chemotherapy; cisplatin; glutathione; GST; GSTM1; GSTP1; hearing impairment; hearing loss; ototoxicity; pharmacogenetics; polymorphism; tinnitus
Categories
Ask authors/readers for more resources
Cisplatin induces ototoxicity with a huge interindividual variation, which is at least partly based on genetic differences between the affected individuals. Identification of genetic variants that could predict the severity of ototoxicity is an important step towards a more individualized cisplatin treatment. Nevertheless, so far, only a few studies have assessed this issue. This review will address the prevalence of cisplatin-induced ototoxicity, its pathophysiology, quantification and associations with genetic variants. The recent progress in both phenotyping and genotyping is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available